BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25092686)

  • 1. Glucose counterregulation in advanced type 2 diabetes: effect of β-adrenergic blockade.
    Bokhari S; Plummer E; Emmerson P; Gupta A; Meyer C
    Diabetes Care; 2014 Nov; 37(11):3040-6. PubMed ID: 25092686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing the decrement in insulin secretion improves glucagon responses to hypoglycemia in advanced type 2 diabetes.
    Israelian Z; Gosmanov NR; Szoke E; Schorr M; Bokhari S; Cryer PE; Gerich JE; Meyer C
    Diabetes Care; 2005 Nov; 28(11):2691-6. PubMed ID: 16249541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple defects in counterregulation of hypoglycemia in modestly advanced type 2 diabetes mellitus.
    Israelian Z; Szoke E; Woerle J; Bokhari S; Schorr M; Schwenke DC; Cryer PE; Gerich JE; Meyer C
    Metabolism; 2006 May; 55(5):593-8. PubMed ID: 16631434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia.
    Rizza RA; Cryer PE; Gerich JE
    J Clin Invest; 1979 Jul; 64(1):62-71. PubMed ID: 36413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Counterregulatory responses to hypoglycemia differ between glimepiride and glyburide in non diabetic individuals.
    Joy NG; Tate DB; Davis SN
    Metabolism; 2015 Jun; 64(6):729-37. PubMed ID: 25765720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal and metabolic counterregulation during and after high-dose insulin-induced hypoglycemia in diabetes mellitus type 2.
    Bischof MG; Ludwig C; Hofer A; Kletter K; Krebs M; Stingl H; Nowotny P; Waldhäusl W; Roden M
    Horm Metab Res; 2000 Oct; 32(10):417-23. PubMed ID: 11069207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term ingestion of Ginkgo biloba extract does not alter whole body insulin sensitivity in non-diabetic, pre-diabetic or type 2 diabetic subjects--a randomized double-blind placebo-controlled crossover study.
    Kudolo GB; Wang W; Elrod R; Barrientos J; Haase A; Blodgett J
    Clin Nutr; 2006 Feb; 25(1):123-34. PubMed ID: 16293352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes.
    Porcellati F; Lucidi P; Cioli P; Candeloro P; Marinelli Andreoli A; Marzotti S; Ambrogi M; Bolli GB; Fanelli CG
    Diabetes Care; 2015 Mar; 38(3):503-12. PubMed ID: 25524950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.
    Gastaldelli A; Cusi K; Pettiti M; Hardies J; Miyazaki Y; Berria R; Buzzigoli E; Sironi AM; Cersosimo E; Ferrannini E; Defronzo RA
    Gastroenterology; 2007 Aug; 133(2):496-506. PubMed ID: 17681171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion.
    de la Peña A; Loghin C; Cui X; Zhang X; Kapitza C; Kelly RP
    Diabetes Obes Metab; 2017 Apr; 19(4):517-523. PubMed ID: 27976833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The adrenergic contribution to glucose counterregulation in type I diabetes mellitus. Dependency on A-cell function and mediation through beta 2-adrenergic receptors.
    De Feo P; Bolli G; Perriello G; De Cosmo S; Compagnucci P; Angeletti G; Santeusanio F; Gerich JE; Motolese M; Brunetti P
    Diabetes; 1983 Oct; 32(10):887-93. PubMed ID: 6311652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis.
    Lucidi P; Rossetti P; Porcellati F; Pampanelli S; Candeloro P; Andreoli AM; Perriello G; Bolli GB; Fanelli CG
    Diabetes; 2010 Jun; 59(6):1349-57. PubMed ID: 20299466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
    Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
    Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of glucose homeostasis in humans with denervated livers.
    Perseghin G; Regalia E; Battezzati A; Vergani S; Pulvirenti A; Terruzzi I; Baratti D; Bozzetti F; Mazzaferro V; Luzi L
    J Clin Invest; 1997 Aug; 100(4):931-41. PubMed ID: 9259593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating endothelin-1 levels increase during euglycemic hyperinsulinemic clamp in lean NIDDM men.
    Ferri C; Carlomagno A; Coassin S; Baldoncini R; Cassone Faldetta MR; Laurenti O; Properzi G; Santucci A; De Mattia G
    Diabetes Care; 1995 Feb; 18(2):226-33. PubMed ID: 7729302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
    Hare KJ
    Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients.
    Bajaj M; Suraamornkul S; Hardies LJ; Pratipanawatr T; DeFronzo RA
    Int J Obes Relat Metab Disord; 2004 Jun; 28(6):783-9. PubMed ID: 15024400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No effect of beta-adrenergic blockade on hypoglycaemic effect of glucagon-like peptide-1 (GLP-1) in normal subjects.
    Toft-Nielsen M; Hvidberg A; Hilsted J; Dige-Petersen H; Holst JJ
    Diabet Med; 1996 Jun; 13(6):544-8. PubMed ID: 8799658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.